Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label, Multi-cohort Study of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cell, in Adults With Autoimmune Diseases

NCT07295847 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07295847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07295847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label, Multi-cohort Study of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cell, in Adults With Autoimmune Diseases
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Recruiting
Start date
January 9, 2026
Completion date
February 22, 2028
Enrollment
27 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic inflammatory myopathies, rheumatoid arthritis, systemic sclerosis